MedPath

Effect of Safoof-e-Ziabetus in the management of Ziabetus Shakri ( Type 2 Diabetes Mellitus.

Phase 2
Conditions
Health Condition 1: E119- Type 2 diabetes mellitus without complications
Registration Number
CTRI/2022/02/040327
Lead Sponsor
Central Council of Research in Unani Medicine New Delhi
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Patients of any gender (Male,Female,Transgender)in the age group of 20-70 yrs of age.

Fasting Plasma Glucose levels in the range of 126-150 mg/dl.

Post Prandial Plasma Glucose levels between 200-250 mg/dl.

Patients having ALT,AST,Sr.Creatinine, Blood Urea with normal limits.

Patients ready to participate in the study and willing to follow the instructions.

Exclusion Criteria

Patients with Fasting Plasma Glucose level >150 mg/dl

Postprandial Plasma Glucose level >250 mg/dl

-Diabetes Mellitus associated with complications of Ketoacidosis

Diabetes Mellitus Type-I/ Diabetes Insipidus/ Patients on Insulin therapy

Significant Pulmonary/Cardiovascular/Hepato-renal Dysfunction

Pregnant and lactating women

Complications (microangiopathies) associated with longstanding Diabetes like Diabetic Neuropathy, Diabetic Nephropathy and Diabetic Retinopathy

Patients having malignancy

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Glycemic Control in Type 2 Diabetes MellitusTimepoint: 45 days
Secondary Outcome Measures
NameTimeMethod
Haematological and biochemical Evaluation of SafetyTimepoint: 45 days
© Copyright 2025. All Rights Reserved by MedPath